After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

Viatris (VTRS) stock dips after its experimental therapy for eyelid inflammation fails a Phase 3 trial. Read more here.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Shares of Viatris Inc. VTRS advanced 1.41% to $9.37 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 and ...

Viatris said on Friday that its experimental ophthalmic ointment failed to meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.